ERBB3 and breast cancer: Similar findings were recently demonstrated by Balz et al. demonstrating that the EGF induced calcium influx concomitant with the migratory activity was markedly decreased in EGFR/HER2/HER3 positive MDA-HER2 breast cancer cells treated with the PI3K inhibitor wortmannin [47].